A little-known herbal medicine firm is now making big waves on Wall Street. Regencell Bioscience, a Hong Kong-based biotech company, has shocked global markets with a staggering stock surge of over 46,000 per cent this year, despite having no profits, no chief medical officer, and limited commercial operations.&nbsp;As a result, its founder and CEO, Yat-Gai Au, has seen his net worth balloon to over $25 billion, placing him among the world’s 100 richest people, as per Bloomberg.<h2>The meteoric rise of Regencell</h2>Regencell Bioscience was virtually unknown until recently. Traded as a micro-cap on the Nasdaq, the company develops traditional Chinese medicine (TCM) formulas targeting conditions like ADHD and autism spectrum disorder.&nbsp;But the real twist? It has never turned a profit.&nbsp;The company posted a $4.4 million loss in the fiscal year ending June 2024 and currently has no official chief medical officer, as per public filings accessed by Bloomberg.&nbsp;Yet, from being valued at just a few million dollars earlier this year, Regencell’s stock has exploded—boosted further by a 38-for-1 forward stock split in June, a move often used to attract retail investors. At one point, its shares soared more than 24 per cent in a single day, with barely 6 per cent of its stock available for public trading.<h2>Who is Yat-Gai Au?</h2>Yat-Gai Au, the man behind Regencell, owns an 86 per cent stake in the firm, now worth over $25 billion on paper.&nbsp;Born with ADHD and dyslexia, Au studied at UC Berkeley’s Haas School of Business and worked at Deutsche Bank in the 1990s before founding Regencell in 2014. According to the company’s website, he has personally invested more than $9 million into the venture, calling it a “passion project” aimed at helping children with neurodevelopmental disorders.&nbsp;The formulas themselves? They’re based on treatments developed by his father, Sik-Kee Au, an electrical engineer turned alternative healer. However, Sik-Kee was once found guilty of professional misconduct by a Hong Kong board for overprescribing medicine in 2021, as per Bloomberg.&nbsp;Regencell’s rally is raising eyebrows among analysts and regulators. With limited float and no concrete commercial success, many compare the surge to earlier meme stock frenzies like GameStop or AMTD Digital.&nbsp;Even more concerning: the firm has disclosed no major scientific breakthroughs or partnerships to justify such a valuation. It simply caught fire in a volatile trading environment—and with such a tightly controlled shareholding structure, even small trades can push prices higher.&nbsp;As of Monday, another investor—Zoom’s early backer Samuel Chen—held a stake worth over $2.2 billion, according to Bloomberg.<h2>From herbs to high stakes</h2>Regencell’s stock story isn’t just about one billionaire. It reflects a wider trend of speculative bubbles in biotech and TCM startups. In 2021, the company signed a deal to distribute Chinese herbal remedies for COVID-19 across Asia—but little has been heard since.&nbsp;The firm’s Brain Theory products, according to its disclosures, are liquid-based herbal formulations administered twice a day. There’s no mention of FDA approval or clinical trial data in the public domain.Still, the stock keeps&nbsp;soaring.<h2>Is it sustainable?</h2>Experts remain sceptical. Regencell has just a dozen employees. Its business model relies heavily on personal branding, self-funding, and a niche medical market with little regulation.&nbsp;Bloomberg analysts warn that “paper wealth” can evaporate as quickly as it appears. With no profits and no product sales, the company’s valuation could collapse just as dramatically as it rose—particularly if scrutiny increases.&nbsp;But for now, Yat-Gai Au stands alongside the world’s wealthiest, thanks to a TCM company that few outside Hong Kong had heard of until this year.&nbsp;(With inputs from the agencies) &nbsp; &nbsp;

Despite posting a $4.4 million loss and lacking a chief medical officer or significant commercial success, CEO Yat-Gai Au's wealth has surpassed $25 billion, placing him among the world richest.

A little-known herbal medicine firm is now making big waves on Wall Street. Regencell Bioscience, a Hong Kong-based biotech company, has shocked global markets with a staggering stock surge of over 46,000 per cent this year, despite having no profits, no chief medical officer, and limited commercial operations. As a result, its founder and CEO, Yat-Gai Au, has seen his net worth balloon to over $25 billion, placing him among the world’s 100 richest people, as per Bloomberg. The meteoric rise of Regencell Regencell Bioscience was virtually unknown until recently. Traded as a micro-cap on the Nasdaq, the company develops traditional Chinese medicine (TCM) formulas targeting conditions like ADHD and autism spectrum disorder. But the real twist? It has never turned a profit. The company posted a $4.4 million loss in the fiscal year ending June 2024 and currently has no official chief medical officer, as per public filings accessed by Bloomberg. Yet, from being valued at just a few million dollars earlier this year, Regencell’s stock has exploded—boosted further by a 38-for-1 forward stock split in June, a move often used to attract retail investors. At one point, its shares soared more than 24 per cent in a single day, with barely 6 per cent of its stock available for public trading. Who is Yat-Gai Au? Yat-Gai Au, the man behind Regencell, owns an 86 per cent stake in the firm, now worth over $25 billion on paper. Born with ADHD and dyslexia, Au studied at UC Berkeley’s Haas School of Business and worked at Deutsche Bank in the 1990s before founding Regencell in 2014. According to the company’s website, he has personally invested more than $9 million into the venture, calling it a “passion project” aimed at helping children with neurodevelopmental disorders. The formulas themselves? They’re based on treatments developed by his father, Sik-Kee Au, an electrical engineer turned alternative healer. However, Sik-Kee was once found guilty of professional misconduct by a Hong Kong board for overprescribing medicine in 2021, as per Bloomberg. Regencell’s rally is raising eyebrows among analysts and regulators. With limited float and no concrete commercial success, many compare the surge to earlier meme stock frenzies like GameStop or AMTD Digital. Even more concerning: the firm has disclosed no major scientific breakthroughs or partnerships to justify such a valuation. It simply caught fire in a volatile trading environment—and with such a tightly controlled shareholding structure, even small trades can push prices higher. As of Monday, another investor—Zoom’s early backer Samuel Chen—held a stake worth over $2.2 billion, according to Bloomberg. From herbs to high stakes Regencell’s stock story isn’t just about one billionaire. It reflects a wider trend of speculative bubbles in biotech and TCM startups. In 2021, the company signed a deal to distribute Chinese herbal remedies for COVID-19 across Asia—but little has been heard since. The firm’s Brain Theory products, according to its disclosures, are liquid-based herbal formulations administered twice a day. There’s no mention of FDA approval or clinical trial data in the public domain. Still, the stock keeps soaring. Is it sustainable? Experts remain sceptical. Regencell has just a dozen employees. Its business model relies heavily on personal branding, self-funding, and a niche medical market with little regulation. Bloomberg analysts warn that “paper wealth” can evaporate as quickly as it appears. With no profits and no product sales, the company’s valuation could collapse just as dramatically as it rose—particularly if scrutiny increases. But for now, Yat-Gai Au stands alongside the world’s wealthiest, thanks to a TCM company that few outside Hong Kong had heard of until this year. (With inputs from the agencies)

Regencell Bioscience, a Hong Kong-based biotech firm specializing in traditional Chinese medicine (TCM), has experienced a staggering stock surge of over 46,000% this year, raising concerns among analysts and regulators.

Here's how an unprofitable Chinese medicine firm’s stock rally lifts CEO’s wealth to $33 billion

A Chinese-owned mine in Zambia has unleashed an environmental disaster, spilling 50 million liters of acidic waste into a river. The toxic spill turned the water deadly overnight, destroying marine life and endangering local communities. Activists are calling for accountability as concerns over pollution and corporate negligence grow.

Acidic waste spill at a Chinese-owned mine spills into river

A Chinese-owned mine in Zambia has unleashed an environmental disaster, spilling 50 million liters of acidic waste into a river. The toxic spill turned the water deadly overnight, destroying marine life and endangering local communities. Activists are calling for accountability as concerns over pollution and corporate negligence grow

50 million litres of poison unleashed, river turns toxic overnight

A Chinese company’s purchase of an American farmland near a military base has sparked concerns among US lawmakers who have shot off a letter to the Government Accountability Office, highlighting the security implications of such deals.

Earlier this month, around 130 lawmakers requested the agency to analyse the security implications of the Chinese ownership of US agricultural land.

"China's ownership of US farmland is a threat to our food security and national security," James Comer, the Republican member of the House Committee on Oversight and Reform, said in a press release.

In the letter, the lawmakers called on the GAO to find a potential threat to America's food supply in light of the purchase and subsequently inform Congress how to "best protect the security of the American people."

The concerns were raised after a Chinese agricultural company, Fufeng Group, in November last year bought 370 acres (150 hectares) of land in Grand Forks, North Dakota, around 20 kilometres from a US Air Force base, which houses some of the most advanced drones, reports Nikkei Asia newspaper.

Fufeng on its website said that the land will be used for a wet corn milling facility to extract high-value amino acids, lysine and threonine to be used in animal feed. It said that most of the products will be sold in North America.

However, General Atomics Aeronautical Systems, which is responsible for&nbsp;developing the&nbsp;unmanned aircraft systems at the air base, in a statement had opposed the move and called on the Biden administration to pause the project.

"Chinese business efforts are inextricably linked with Chinese government efforts. We can't ignore the opportunity for sophisticated military espionage to co-locate itself within a Chinese business of such scale and scope. Given the proximity to critical national airspace and sensitive military operations on and around Grand Forks Air Force Base, American leaders should be very, very concerned,” General Atomics Aeronautical Systems spokesman&nbsp;Mark Brinkley said.

According to Nikkei Asia newspaper, foreign ownership of American farmlands has doubled in the past decade.

Data by the US Department of Agriculture shows that as of December 2020, 37.6 million acres (15.2 million hectares) of US farmland are owned by foreign individuals and entities.

Canada topped the list with 12.4 million acres, or 32 per cent of the total, followed by the Netherlands, Italy, the UK and Germany.

China holds less than 1 per cent of American farmland with 352,140 acres.

(With inputs from agencies)

WATCH WION LIVE HERE: 

<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" loading="”lazy”" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe>

A Chinese company’s purchase of an American farmland near a military base has sparked concerns among US lawmakers who have shot off a letter to the Government Accountability Office, highlighting the security implications of such deals.

A Chinese company’s purchase of an American farmland near a military base has sparked concerns among US lawmakers who have shot off a letter to the Government Accountability Office, highlighting the security implications of such deals. Earlier this month, around 130 lawmakers requested the agency to analyse the security implications of the Chinese ownership of US agricultural land. "China's ownership of US farmland is a threat to our food security and national security," James Comer, the Republican member of the House Committee on Oversight and Reform, said in a press release. In the letter, the lawmakers called on the GAO to find a potential threat to America's food supply in light of the purchase and subsequently inform Congress how to "best protect the security of the American people." The concerns were raised after a Chinese agricultural company, Fufeng Group, in November last year bought 370 acres (150 hectares) of land in Grand Forks, North Dakota, around 20 kilometres from a US Air Force base, which houses some of the most advanced drones, reports Nikkei Asia newspaper. Fufeng on its website said that the land will be used for a wet corn milling facility to extract high-value amino acids, lysine and threonine to be used in animal feed. It said that most of the products will be sold in North America. However, General Atomics Aeronautical Systems, which is responsible for developing the unmanned aircraft systems at the air base, in a statement had opposed the move and called on the Biden administration to pause the project. "Chinese business efforts are inextricably linked with Chinese government efforts. We can't ignore the opportunity for sophisticated military espionage to co-locate itself within a Chinese business of such scale and scope. Given the proximity to critical national airspace and sensitive military operations on and around Grand Forks Air Force Base, American leaders should be very, very concerned,” General Atomics Aeronautical Systems spokesman Mark Brinkley said. According to Nikkei Asia newspaper, foreign ownership of American farmlands has doubled in the past decade. Data by the US Department of Agriculture shows that as of December 2020, 37.6 million acres (15.2 million hectares) of US farmland are owned by foreign individuals and entities. Canada topped the list with 12.4 million acres, or 32 per cent of the total, followed by the Netherlands, Italy, the UK and Germany. China holds less than 1 per cent of American farmland with 352,140 acres. (With inputs from agencies) WATCH WION LIVE HERE:

Chinese firm’s purchase of American farmland near military base sparks concerns

Hong Kong is facing a coronavirus (COVID-19) surge with reports of bodies being "piled up together" for funerals and authorities are running short of traditional wooden coffins.&nbsp;

As reported by the news agency Reuters, Hong Kong has recorded more than a million infections and more than 8,000 deaths since the fifth wave of coronavirus hit the global financial hub.&nbsp;

Amid the rise in cases, some pharma firms are making profits globally. For example, the latest data by Bloomberg shows how Chinese Pharma firm Kintor Pharmaceutical Ltd surged to 229 per cent in Hong Kong.&nbsp;

ALSO WATCH | <a href="https://www.wionews.com/trending/watch-chinese-people-claim-quarantine-facilities-in-shanghai-have-insufficient-staff-shortage-of-food-468545">Shanghai residents claim quarantine facilities have insufficient staff, shortage of food</a>

The rise was witnessed after the firm stated its drug reduces Covid deaths and is quite effective in reducing the risk of hospitalisation. The comments raised the prospect of a first homegrown antiviral treatment.&nbsp;

The Bloomberg report published on April 6 stated that shares of the company were up 141 per cent as of 11:06 am (local time) after earlier surging as much as 229 per cent. This is said to be the biggest jump after the company got listed in Hong Kong in mid-2020.&nbsp;

All this has happened after the company released a <a href="https://www.prnewswire.com/news-releases/kintor-pharmas-proxalutamide-demonstrated-reduction-in-hospitalizationmortality-for-patients-with-mild-to-moderate-covid-19-in-phase-iii-mrct-study-301518525.html">statement</a> related to its effectiveness. Kintor announced the top-line results of the Phase III MRCT of proxalutamide in outpatients with mild to moderate COVID-19 regardless of vaccination status and risk factors.&nbsp;

ALSO READ |&nbsp;<a href="https://www.wionews.com/world/shanghais-covid-mission-impossible-38k-health-workers-deployed-sampling-of-25-million-residents-completed-468430" hreflang="en">Shanghai's 'mission impossible': 38k health workers conduct citywide sampling</a>

As per the statement, data from the study demonstrated that the protection rate of patients in the trial (regardless of age or risk factors) treated with proxalutamide for more than seven days reached 100% (p &lt; 0.02).&nbsp;

"The treatment with proxalutamide significantly reduced hospitalization or death in COVID-19 patients, especially in the middle-aged and elderly with high-risk factors," the statement added.&nbsp;

WATCH |&nbsp;China reports highest ever-daily cases, 'Shanghai insufficiently prepared,' says top official

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/china-reports-highest-ever-daily-cases-shanghai-insufficiently-prepared-says-top-official-468761/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>
</div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

&nbsp;

Hong Kong is facing a coronavirus (COVID-19) surge with reports of bodies being "piled up together" for funerals and authorities are running short of traditional wooden coffins.

Hong Kong is facing a coronavirus (COVID-19) surge with reports of bodies being "piled up together" for funerals and authorities are running short of traditional wooden coffins. As reported by the news agency Reuters, Hong Kong has recorded more than a million infections and more than 8,000 deaths since the fifth wave of coronavirus hit the global financial hub. Amid the rise in cases, some pharma firms are making profits globally. For example, the latest data by Bloomberg shows how Chinese Pharma firm Kintor Pharmaceutical Ltd surged to 229 per cent in Hong Kong. ALSO WATCH | Shanghai residents claim quarantine facilities have insufficient staff, shortage of food The rise was witnessed after the firm stated its drug reduces Covid deaths and is quite effective in reducing the risk of hospitalisation. The comments raised the prospect of a first homegrown antiviral treatment. The Bloomberg report published on April 6 stated that shares of the company were up 141 per cent as of 11:06 am (local time) after earlier surging as much as 229 per cent. This is said to be the biggest jump after the company got listed in Hong Kong in mid-2020. All this has happened after the company released a statement related to its effectiveness. Kintor announced the top-line results of the Phase III MRCT of proxalutamide in outpatients with mild to moderate COVID-19 regardless of vaccination status and risk factors. ALSO READ | Shanghai's 'mission impossible': 38k health workers conduct citywide sampling As per the statement, data from the study demonstrated that the protection rate of patients in the trial (regardless of age or risk factors) treated with proxalutamide for more than seven days reached 100% (p < 0.02). "The treatment with proxalutamide significantly reduced hospitalization or death in COVID-19 patients, especially in the middle-aged and elderly with high-risk factors," the statement added. WATCH | China reports highest ever-daily cases, 'Shanghai insufficiently prepared,' says top official ×

Chinese firm surges 229% in Hong Kong after claims its Covid drug reduces deaths and hospitalisation: Report

The Trump administration is revoking certain licenses to sell the semiconductor products from Chinese firm Huawei and intends to reject dozens of other applications to supply the telecommunications firm.

US government to revoke license to sell products to Huawei

Congress general secretary Priyanka Gandhi Vadra on Thursday accused the government of adopting a weak strategy and kneeling down before China by "handing over" a rail contract to a Chinese firm.

She said the Centre should give a strong message to China.

<a href="https://www.wionews.com/videos/india-responds-to-claim-over-galwan-valley-china-making-inevitable-claims-306738">Also watch|&nbsp;India responds to claim over Galwan valley: China making 'inevitable' claims</a>

"Twenty of our soldiers have been martyred. In such a situation, the central government should give a strong message, but the government has adopted a weak strategy of kneeling down by handing over the contract of Delhi-Meerut semi high-speed rail corridor to a Chinese company. All Indian companies are also competent to build this corridor," she said in a tweet in Hindi.

She also shared a media report claiming that a Chinese company has got the Rs 1126 crore contract for Delhi-Meerut rapid rail, amid the stand-off between Indian and Chinese troops.

Twenty Indian soldiers lost their lives in a violent clash between the troops of India and China at Galwan Valley in Ladakh on Monday night.&nbsp;

Congress general secretary Priyanka Gandhi Vadra on Thursday accused the government of adopting a weak strategy and kneeling down before China by "handing over" a rail contract to a Chinese firm.

Congress general secretary Priyanka Gandhi Vadra on Thursday accused the government of adopting a weak strategy and kneeling down before China by "handing over" a rail contract to a Chinese firm. She said the Centre should give a strong message to China. Also watch| India responds to claim over Galwan valley: China making 'inevitable' claims "Twenty of our soldiers have been martyred. In such a situation, the central government should give a strong message, but the government has adopted a weak strategy of kneeling down by handing over the contract of Delhi-Meerut semi high-speed rail corridor to a Chinese company. All Indian companies are also competent to build this corridor," she said in a tweet in Hindi. She also shared a media report claiming that a Chinese company has got the Rs 1126 crore contract for Delhi-Meerut rapid rail, amid the stand-off between Indian and Chinese troops. Twenty Indian soldiers lost their lives in a violent clash between the troops of India and China at Galwan Valley in Ladakh on Monday night.

Govt adopting weak strategy by handing over rail contract to Chinese firm: Priyanka Gandhi

By spying on Huawei, U.S. found evidence against the Chinese firm

chinese-firm

Chinese Firm, News on Chinese Firm, stories on Chinese Firm, articles on Chinese Firm, Chinese Firm stories at Wion, Chinese Firm news, Chinese Firm latest news

chinese firm